The calm after the cytokine storm: lessons from the TGN1412 trial
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index; 16 of the 32 sources its claims cite were checked for support.
Abstract
In March 2006, a phase I study of the superagonistic anti-CD28 antibody TGN1412 caused a massive cytokine storm and multiorgan failure in six healthy human volunteers. Such a profound impact on the immune system was not predicted by preclinical animal studies. In a study from this issue of the JCI, Müller et al. treated rats with the superagonistic anti-CD28 antibody JJ316 and found that it rapidly induced a marked T cell lymphopenia by trapping T cells in the spleen and lymph nodes (see the related article beginning on page 1405). This dramatic redistribution of T cells simulated the profound T cell lymphopenia observed in human recipients of TGN1412. In contrast, JJ316 treatment in the rats did not reproduce the massive cytokine storm observed following TGN1412 administration to the human volunteers. These results point to similarities as well as differences between rodents and humans in the immunological effects of superagonistic anti-CD28 antibody treatment and raise further questions about how best to design preclinical studies that can better predict the risks of novel immunotherapeutics in humans.
Overview
CoChat Summary
TL;DR
This commentary reviews the 2006 Northwick Park TGN1412 disaster, in which a superagonistic anti-CD28 antibody caused a massive cytokine storm and multiorgan failure in six healthy volunteers, and asks why preclinical animal studies failed to predict it. It highlights Müller et al.'s accompanying rat study showing that the rat-equivalent antibody JJ316 reproduces the T cell lymphopenia but not the cytokine storm, and endorses the Expert Scientific Group's 22 recommendations for first-in-human trials.
Key findings
All six volunteers receiving TGN1412 developed a systemic inflammatory response within 90 minutes, with profound lymphopenia nadir at 24 hours, multiorgan failure lasting 1–2 weeks, and gradual improvement over 2–4 weeks; the batch was later found free of endotoxin or manufacturing error, implicating CD28 ligation itself. The starting dose of 0.1 mg/kg was a 500th of the no-observed-adverse-effect level (50 mg/kg) in nonhuman primates, where only moderate IL-2, IL-5, and IL-6 rises occurred with no significant IL-4, IFNγ, or TNFα changes. Müller et al. found JJ316 in rats caused rapid redistribution of all CD4+ T cells to spleen and lymph nodes via reduced motility, increased adhesion to fibronectin, and downregulated EDG-1, plus two waves of T cell activation — but only mildly elevated TNFα and IFNγ, orders of magnitude below human levels. Stebbings et al. showed TGN1412 induced large TNFα, IL-6, and IL-8 release from human PBMCs (air-dried, 1.0 and 10.0 μg/well) and in PBMC–endothelial coculture, but not from cynomolgus PBMCs.
Methods
Narrative commentary/retrospective review of the TGN1412 phase I trial, the TeGenero investigator brochure, the MHRA evaluation, and the ESG report, synthesizing these with the accompanying Müller et al. rat study and other published preclinical work (Stebbings et al., Legrand et al., Nguyen et al.). No primary data collection; the paper's own analysis is interpretive.
Limitations
The paper states it will probably never be known whether a lower starting dose would have attenuated the adverse events. Evident from the text: this is a commentary rather than an original study, so its claims rest on secondary sources; the rat model (JJ316) only partially mimics human responses, and the human CD28 sequence differs from macaque by four amino acids including a G68E substitution, limiting cross-species extrapolation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 3 Not valid · 14 Not checked · 17 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Müller et al. treated rats with the superagonistic anti-CD28 antibody JJ316 and found that it rapidly induced a marked T cell lymphopenia by trapping T cells in the spleen and lymph nodes”
What the sources say
- Supportedcites [5] Müller, 2008, J. Clin. Invest. source
The Introduction states that JJ316 infusion in rats rapidly arrests T cells in the spleen and lymph nodes, redistributing them from the periphery and causing severe T lymphopenia. The Discussion likewise describes T-cell trapping in secondary lymphoid organs and lymphopenia lasting 24–48 hours. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In contrast, JJ316 treatment in the rats did not reproduce the massive cytokine storm observed following TGN1412 administration to the human volunteers.”
What the sources say
- Supportedcites [5] Müller, 2008, J. Clin. Invest. source
The Introduction says that TGN1412 caused a systemic inflammatory response in human volunteers, whereas cytokine serum levels after JJ316 treatment in rats remained moderate. The Figure 7 passage explicitly contrasts the human trial’s massive cytokine storm with its absence in JJ316-treated rats. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“similar reagents had shown efficacy in rodent models for treating autoimmune disease (2-4).”
What the sources say
- Supportedcites [2] matched to “Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis” (2005) source
The Results section, “Superagonistic CD28–specific mAbs ameliorate disease activity in EAE,” reports that superagonistic anti-CD28 antibodies were effective in two rat models of experimental autoimmune encephalomyelitis. It also reports reduced disease severity after treatment with JJ316, supporting the claim that similar reagents had shown efficacy in rodent models of autoimmune disease. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [3] matched to “Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies” (2003) source
- Not checked — no full text of the sourcecites [4] Rodríguez-Palmero, 2006, J. Rheumatol.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Also, a similar cytokine release profile was obtained when TGN1412 (0.1, 1.0, and 10 μ g/well) was added in aqueous solution to a coculture of human PBMCs and endothelial cells.”
What the sources say
- Supportedcites [11] Stebbings, 2007, J. Immunol. source
The Results report that aqueous TGN1412 at 0.1, 1.0, and 10 μg/well stimulated TNF-α, IL-6, and IL-8 release from a coculture of PBMCs and human endothelial cells. The Methods identify the PBMCs as isolated from human blood. The Results also report release of those same cytokines in the preceding experiments, supporting the description of a similar profile. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Müller et al. went on to show that, in addition, JJ316 impaired T cell egress from the spleen and lymph nodes via the downregulation of the sphingosine 1phosphate receptor EDG-1 that is predominantly expressed on T cells.”
What the sources say
- Supportedcites [5] Müller, 2008, J. Clin. Invest. source
The discussion passage labeled Figure 7 says JJ316 downregulates EDG-1 on T lymphocytes, impairing their migration along an S1P gradient. It also identifies EDG-1 as the S1P receptor predominantly expressed on T lymphocytes that guides their egress from the spleen and lymph nodes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
14 more claims · 1 with their cited sources checked
Create a free account to see all 50 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 13
- Not yet classified. 9
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Developing expertise
“Data are from ref. 4.”
§ Call to action
“The ESG made 22 recommendations, encompassing various aspects of the drug development process (9).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ CD28 superagonist-induced T lymphopenia: new insights
“The authors showed, via intravital video microscopy, that T cell motility was dramatically reduced immediately following TGN1412 administration”
§ CD28 superagonist-induced T lymphopenia: new insights
“These authors found that i.v. infusion of rats with JJ316, the rat functional equivalent of TGN1412”
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316
Loss of Siglec expression on T lymphocytes during human evolution
Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P., & Varki, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510484103 · Cited by 204
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Establishing risk of human experimentation with drugs: lessons from TGN1412
Kenter, M., & Cohen, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69562-7 · Cited by 153
Legrand, N., Cupedo, T., van Lent, A. U., Ebeli, M. J., Weijer, K., Hanke, T., & Spits, H. (2006) · Blood · doi:10.1182/blood-2006-01-0190 · Cited by 82
Schmidt, J., Elflein, K., Stienekemeier, M., Rodriguez-Palmero, M., Schneider, C., Toyka, K. V., Gold, R., & Hünig, T. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00182-6 · Cited by 59
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies
Hünig, T. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)95004-x · Cited by 57
A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats
Müller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flügel, A., & Reichardt, H. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32698 · Cited by 46
(2006) · PubMed · Cited by 44
Research works printed but not linked: 2
- Rodríguez-Palmero, 2006, J. Rheumatol., 33, 110
- TeGenero AG Investigator’s Brochure. TGN1412 humanized agonistic anti-CD28 monoclonal antibody. Edition 1.1. http://www.circare.org/foia5/tgn1412investigatorbrochure.pdf.
Cited by
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Immunopathogenesis and treatment of cytokine storm in COVID-19
Kim, J. S., Lee, J. Y., Yang, J. W., Lee, K. H., Effenberger, M., Szpirt, W., Kronbichler, A., & Shin, J. I. (2021) · Theranostics · doi:10.7150/thno.49713 · Cited by 463
Marx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295
“…et al., 1965; Woollam, 1965; Bauer et al.,1998; Stephens and Fillmore, 2000 Somia and Verma, 2000; Edwards, 2004 Dieppe et al., 2004; Arbor, 2004 Clair, 2008; Stebbings et al., 2012 Jouan, 2016; Mileni et al., 2008 Adverse Outcome Pathway / Mode of Action It was administered as a sleeping…”
Marx, U., Walles, H., Hoffmann, S., Lindner, G., Horland, R., Sonntag, F., Klotzbach, U., Sakharov, D., Tonevitsky, A., & Lauster, R. (2012) · Alternatives to Laboratory Animals · doi:10.1177/026119291204000504 · Cited by 177
Immunotoxicity of monoclonal antibodies
Descotes, J. (2009) · mAbs · doi:10.4161/mabs.1.2.7909 · Cited by 140
Cancer and Aging - the Inflammatory Connection
Zinger, A., Cho, W. C., & Ben-Yehuda, A. (2017) · Aging and disease · doi:10.14336/ad.2016.1230 · Cited by 136
Structure and Composition Define Immunorecognition of Nucleic Acid Nanoparticles
Hong, E., Halman, J. R., Shah, A. B., Khisamutdinov, E. F., Dobrovolskaia, M. A., & Afonin, K. A. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01283 · Cited by 136
Nanoparticle-induced immune response: Health risk versus treatment opportunity?
Pondman, K. M., Gac, S. L., & Kishore, U. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152317 · Cited by 130
Yiu, H., Graham, A. L., & Stengel, R. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045027 · Cited by 122
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
Lu, J., Lee-Gabel, L., Nadeau, M. C., Ferencz, T. M., & Soefje, S. A. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214538087 · Cited by 103
CD28 Co-Stimulation Down Regulates Th17 Development
Bouguermouh, S., Fortin, G., Baba, N., Rubio, M., & Sarfati, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005087 · Cited by 101
Krusch, M., Salih, J., Schlicke, M., Baessler, T., Kampa-Schittenhelm, K. M., Mayer, F., & Salih, H. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902404 · Cited by 92
Horvath, C. J., & Milton, M. N. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332986 · Cited by 87
“It has been suggested that regulatory authorities may have reconsidered the wisdom of dosing NHVs with TGN1412 if they were aware of this information (St. Clair 2008).”
BackgroundDisplay scaffolds: protein engineering for novel therapeutics
Nuttall, S. D., & WALSH, R. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.007 · Cited by 87
Rational Design of Mouse Models for Cancer Research
Landgraf, M., McGovern, J., Friedl, P., & Hutmacher, D. W. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.12.001 · Cited by 85
What is a Humanized Mouse? Remaking the Species and Spaces of Translational Medicine
Davies, G. F. (2012) · Body & Society · doi:10.1177/1357034x12446378 · Cited by 81
Safety of biologics, lessons learnt from TGN1412
Stebbings, R., Poole, S., & Thorpe, R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.002 · Cited by 70
Leclercq-Cohen, G., Steinhoff, N., Haegel, H., Marco, D. D., Bacac, M., & Klein, C. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2083479 · Cited by 72
Human immunity in vitro — Solving immunogenicity and more
Giese, C., & Marx, U. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.011 · Cited by 67
Zamboni, W. C., Szebeni, J., Kozlov, S., Lucas, A. T., Piscitelli, J. A., & Dobrovolskaia, M. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.012 · Cited by 66
Jiménez, S. A., & Piera-Velázquez, S. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.04.004 · Cited by 65
Public awareness and views on unlicensed use of medicines in children
Mukattash, T. L., Millership, J. S., Collier, P. S., et al. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03290.x · Cited by 57
In vitro toxicity model: Upgrades to bridge the gap between preclinical and clinical research
Madorran, E., Stožer, A., Bevc, S., & Maver, U. (2020) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2019.4378 · Cited by 82
Immunotherapeutic strategies in autoimmune uveitis
Papotto, P. H., Marengo, E. B., Sardinha, L. R., Goldberg, A. C., & Rizzo, L. V. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.05.003 · Cited by 47
Ebola virus-mediated T-lymphocyte depletion is the result of an abortive infection
Younan, P. M., Santos, R. I., Ramanathan, P., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008068 · Cited by 47
CCC meets ICU: Redefining the role of critical care of cancer patients
von Bergwelt‐Baildon, M., Hallek, M. J., Shimabukuro‐Vornhagen, A., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-612 · Cited by 40
Moreira, A., Müller, M., Costa, P. F., & Kohl, Y. (2021) · Advanced Biology · doi:10.1002/adbi.202101139 · Cited by 52
Watterson, C., Lanevschi, A., Horner, J., et al. (2009) · Toxicologic Pathology · doi:10.1177/0192623308329286 · Cited by 35
“In this trial, this type of toxicity resulted in serious adverse events involving all six healthy volunteers (Gribble et al. 2007; St. Clair 2008).”
BackgroundClinically validated approaches to the treatment of autoimmune diseases
Carter, P. H., & Zhao, Q. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903418452 · Cited by 33
Emerson, M. R., Gallagher, R. J., Marquis, J. G., & LeVine, S. M. (2009) · PubMed Central · Cited by 41
Depleting T-cell subpopulations in organ transplantation: T-cell depletion and tolerance
Haudebourg, T., Poirier, N., & Vanhove, B. (2008) · Transplant International · doi:10.1111/j.1432-2277.2008.00788.x · Cited by 35
Chiodin, D., Cox, E. M., Edmund, A. V., Kratz, E., & Lockwood, S. H. (2019) · Clinical and Translational Science · doi:10.1111/cts.12635 · Cited by 31
T regulatory cells in childhood arthritis – novel insights
Pesenacker, A. M., & Wedderburn, L. R. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.14 · Cited by 26
How do we assure the quality of biological medicines?
Longstaff, C., Whitton, C. M., Stebbings, R., & Gray, E. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.010 · Cited by 27
CD28 and ICOS in immune regulation: Structural insights and therapeutic targeting
Upadhyay, S., Kaur, B., & Gabr, M. T. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130310 · Cited by 20
Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals
Reijers, J. A. A., Malone, K. E., Bajramovic, J. J., Verbeek, R., Burggraaf, J., & Moerland, M. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13938 · Cited by 26
Schirrmacher, V., Schlude, C., Weitz, J., & Beckhove, P. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2692 · Cited by 22
Trends in Cell Culture Technology
Marx, U. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3055-1_3 · Cited by 19
Kapiriri, L., Lavery, J. V., SINGER, P. A., Mshinda, H., Babiuk, L. A., & Daar, A. S. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-811 · Cited by 17
Medina, M. Á., Couturier, J. P., Feske, M. L., Mahne, A. E., Turner, M. A., Yu, X., Kozinetz, C. A., Orozco, A. F., Hutchison, A. T., Savidge, T., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0511264 · Cited by 20
Translating Treg Therapy in Humanized Mice
Hahn, S. A., Bellinghausen, I., Trinschek, B., & Becker, C. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00623 · Cited by 21
Avoiding Exploitation in Phase I Clinical Trials: More than (Un)Just Compensation
Lamkin, M., & Elliott, C. (2018) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110518766008 · Cited by 18
Pullen, R. H., Sassano, E. R., Agrawal, P., Escobar, J., Chehtane, M., Schanen, B. C., Drake, D. R., Luna, E., & Brennan, R. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300185 · Cited by 16
Wang, Y. M., & Alexander, S. I. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013070718 · Cited by 15
Ethical considerations and challenges in first-in-human research
Koonrungsesomboon, N., Laothavorn, J., & Karbwang, J. (2016) · Translational research · doi:10.1016/j.trsl.2016.05.006 · Cited by 22
Fundamentals of Clinical Immunotoxicology
House, R. V. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-401-2_24 · Cited by 13
CD28 ligation increases macrophage suppression of T-cell proliferation
Silberman, D., Bucknum, A., Bartlett, T. M., Composto, G. M., Kozlowski, M., Walker, A., Werda, A., Cua, J., Sharpe, A. H., Somerville, J. E., et al. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.13 · Cited by 12
Development of transplant immunosuppressive agents – considerations in the use of animal models
Costello, R., Kissenpfennig, A., Martins, P. N. A., & McDaid, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1535589 · Cited by 13
Papotto, P. H., Marengo, E. B., Sardinha, L. R., Carvalho, K. I., de Carvalho, A. E. Z., Castillo-Méndez, S. I., Jank, C. C., Vanhove, B., Goldberg, A. C., & Rizzo, L. V. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171822 · Cited by 12
Ogasawara, A. K., Kiefer, J. R., Gill, H. S., Chiang, E., Sriraman, S. K., Ferl, G. Z., Ziai, J. M., Bohorquez, S. M. S., Guelman, S. A., Wang, X., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05968-6 · Cited by 13
Johnson, A. M., Barigye, R., & Saminathan, H. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1908060 · Cited by 9
Animal Research Is an Ethical Issue for Humans as Well as for Animals
Archibald, K. (2018) · Journal of Animal Ethics · doi:10.5406/janimalethics.8.1.0001 · Cited by 14
“• Following the infamous clinical trial of TGN1412, a method using human cells was rapidly developed that models the “cytokine storm” suffered by the volunteers (st. clair, 2008).”
MethodCassotta, M., Díaz, Y. A., Qi, Z., Yang, B., Grosso, G., Quiles, J. L., Battino, M. A., Godos, J., & Giampieri, F. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.104980 · Cited by 14
Cytokine Storm in the Pediatric Oncology Patient
Beauchemin, M. (2010) · Journal of Pediatric Oncology Nursing · doi:10.1177/1043454210368533 · Cited by 7
The pathogenesis of infection and immune response
Weston, D. (2010) · British Journal of Nursing · doi:10.12968/bjon.2010.19.sup6.78211 · Cited by 7
Replacing Animal Tests to Improve Safety for Humans
Archibald, K., Coleman, R., & Drake, T. (2019) · BRILL eBooks · doi:10.1163/9789004391192_019 · Cited by 10
Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade
Wu, R. C. H., & Luke, J. J. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2437 · Cited by 5
Significance of biologics in renal transplantation
Grgic, I., & Chandraker, A. K. (2017) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000496 · Cited by 6
Advancing FDA New Approach Methodologies from animal models through digital twins
Eadie, A. L., Lynch, H. F., Scheinerman, N., & Parikh, R. B. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02476-x · Cited by 7
Pulmonary Immunology of Infectious Disease
Burleson, G. R., Burleson, S. C. M., & BURLESON, F. G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-404577-4.00030-8 · Cited by 4
Johnson, V. J., Germolec, D. R., Luebke, R. W., & Luster, M. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99181-5 · Cited by 4
Williamson, D. E. (2014) · Journal of Immunology Research · doi:10.1155/2014/395302 · Cited by 3
Frebel, K., Albring, J. C., Wohlgemuth, A., Schwöppe, C., Hailfinger, S., Lenz, G., & Stelljes, M. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011647 · Cited by 2
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_2 · Cited by 3
Habib, A. G., Nasidi, A., Alder, N. C., et al. (2010) · Toxicon · doi:10.1016/j.toxicon.2010.02.013 · Cited by 2
Phase-I studies and first-in-human trials
Derhaschnig, U., & Jilma, B. (2010) · Springer eBooks · doi:10.1007/978-3-7091-0144-5_7 · Cited by 3
Pirillo, E., Freenor, F., V, Wamba, B. E. N., Bhatnagar, S., Mondal, T., & Tushir‐Singh, J. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110962 · Cited by 3
Phase I Studies and First-In-Human Trials
Derhaschnig, U., & Jilma, B. (2016) · Springer eBooks · doi:10.1007/978-3-319-27347-1_7 · Cited by 2
HUMAN MICRO DOSING STUDIES (PHASE 0): A NOVEL APPROACH IN CLINICAL RESEARCH
Aiswarya, A., & Manohar, V. (2014) · Journal of Pharmaceutical and Scientific Innovation · doi:10.7897/2277-4572.03196 · Cited by 1
Friedman, L. M., Furberg, C. D., & DeMets, D. L. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1586-3_2 · Cited by 1
The Retrovirus Human T Cell Leukemia Virus Type 1 (HTLV-1)
Madrid, J. E. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-62558-9_9 · Cited by 1
The Impact of Novel Technologies on the Environment Throughout History
Ilyinskii, P. (2009) · NATO science for peace and security series. B, Physics and biophysics · doi:10.1007/978-90-481-2523-4_14 · Cited by 1
“The six trial volunteers suffered multiple organ failure which almost killed them, after receiving injections of TGN1412, a monoclonal antibody designed to calm the immune system, but which resulted in a socalled “cytokine storm” or acute immune malfunction [26, 27 ].”
BackgroundPapotto, P. H. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2014.tde-14032015-101012
Long, C. M. (2016) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6108
Safety Considerations for Biologics
Dempster, M., Weir, L. R., & Fagg, R. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch11
A humanized model to investigate targeted therapeutic strategies against cancer bone metastasis
Landgraf, M. (2020) · Queensland University of Technology · doi:10.5204/thesis.eprints.204176
Participant opinions of randomised controlled trials within intellectual disability services
Robotham, D. (2010) · UCL Discovery (University College London)
Boucault, L. (2018) · theses.fr (ABES) · doi:10.70675/e59ab1f0zdf8az4b41za5f9z1f1d0e55aa46
The Tumor Microenvironment: Translating Intravital Insights into Microphysiological Systems
Imparato, G., Mazio, C., Nevola, P., & Netti, P. A. (2026) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-026-00910-4 · Cited by 2
Metadata
- Authors
- St. Clair, E. W.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-04-01
- Volume
- 118
- Issue
- 4
- Pages
- 1344-1347
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2269728
- OpenAlex
- W2066070407
- Cited by
- 79
- References
- 11
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 5 · 2018: 7 · 2017: 5 · 2016: 4 · 2015: 3 · 2014: 7 · 2013: 3 · 2012: 6
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- TGN1412, cytokine storm, T-cell lymphopenia, T cell redistribution, preclinical animal models, multiple organ failure
- MeSH terms
- Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Lymphopenia, Drug Design, Cytokines, CD28 Antigens, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.